Introduction
evidence regarding the effects of virus immunity on gene Adenovirus (Ad) vectors are being widely investigated transfer was obtained from experiments investigating as vehicles for gene delivery in vivo. One particular applilung and liver gene transfer. These tissue sites may be cation for which the vectors are ideally suited is the gene particularly sensitive to humoral Ab responses due to therapy of cancer. The major advantages of Ad vectors their direct contact with the systemic circulation and include: (1) a broad host range in terms of gene transfer; mucosal surfaces. Our interest, on the other hand, focuses (2) easy preparation of high titer stocks (10 11 -10 12 on solid tumors which are often poorly vascularized and p.f.u./ml); (3) a cloning capacity of approximately 8 kb somewhat detached from the systemic circulation. It is in vectors with deletions of early region 1 (E1) and E3 therefore reasonable to speculate that intratumoral gene sequences; and (4) transient expression which limits longtransfer will not be as sensitive to Ad immunity as gene term side-effects (reviewed by Hitt et al 1 ). Studies in anitransfer to other tissues. mal models indicate that efficient gene transfer using Ad Many groups, including ours, are investigating the utilvectors in vivo may be limited by the development of ity of Ads for gene transfer to tumor tissue (reviewed in anti-Ad immunity.
2-5 Humoral responses to the virus Ref. 1). Our studies have involved cytokine gene transfer produce high levels of neutralizing antibodies (Abs) preand we have been successful in producing regressions of venting repeated vector administration 3-5 and cellular established tumors using Ads which express either IL-2, responses result in clearance of virally infected cells by IL-4 or IL-12. [6] [7] [8] Others are using Ads to transfer prodrugcytotoxic T cells (CTLs).
2 As the majority of the human activating enzymes, such as the herpes simplex virus thypopulation has been exposed to Ads during their lifetime, midine kinase gene (HSVtk) and E. coli cytosine deaminprotective immunity may be a potential obstacle to ase (CDA), to render infected cells sensitive to the otherwise nontoxic prodrug (gancyclovir in the case of HSVtk. 9,10 As mentioned above, Ads are reasonable choices as vectors for these therapies because expression the tissues surrounding the site of injection. However, little work has been done to determine the extent to which a replication-deficient Ad will disseminate from the site of injection to infect peripheral organs. The dangers of disseminated virus are greatest with the drugactivating therapies, because this will result in organ destruction in the presence of the prodrug. It is also a major concern for immunotherapies because many of the cytokines can cause profound systemic toxicities if expression is not localized to the tumor.
In this report we show that pre-existing Ad-immunity does not change the outcome of intratumoral treatment with an Ad-expressing IL-12 (AdmIL-12.1). During the course of the studies, we observed that the virus does disseminate in our model following intratumoral administration. It was then demonstrated that Ad-immunity can inhibit vector dissemination indicating that immunity is not a major barrier in this model and may actually be beneficial. We have been studying the immunotherapeutic effects of direct intratumoral injection of cytokine-expressing Ad vectors in a model of polyoma middle T (PymT) induced tested for anti-PyMT CTL. Cytolytic effectors were prebreast adenocarcinoma described by Guy et al. 11 This pared by co-culturing splenocytes from cured animals model is metastatic, phenotypically similar to human with 516MT3 cells, a nontumor cell line which expresses breast adenocarcinoma and provides a defined tumor high levels of the PyMT antigen. A representative experiassociated antigen (PymT). To investigate the effect of ment is shown in Figure 3 . Splenocytes were prepared neutralizing Abs on the outcome of Ad-based immunofrom two Ad-immune mice 21 days following treatment therapy, mice were immunized intranasally (i.n.) with 10 8 with AdmIL-12.1 (the tumor on each animal had p.f.u. of wild-type Ad5. This route produced high levels regressed at this point). Both spleens contained high of circulating neutralizing Abs 4 weeks after immunilevels of anti-PyMT CTL (Ͼ50% lysis at effector to target zation. The Ab titers of two randomly selected animals ratios of 10:1) and the lytic activity was sensitive to the were 264 and 358. Ten days following the immunization, presence of anti-CD3 Ab demonstrating that the 10 6 breast tumor cells were introduced subcutaneously responding population was of T cell origin (data not into the right hind flanks of both Ad-immune and ageshown). A total of five animals from three different matched nonimmune mice and a further 21 days later, experiments were assayed for the presence of Anti-PyMT the tumors were treated by intratumoral injection with CTL and all exhibited similar levels of CTL (data not 5 × 10 8 p.f.u. of AdmIL-12.1. This treatment has been shown). We also tested for CTL activity in the spleens shown to induce regression of greater than 75% of treated from Ad-immune tumor-bearing animals 21 days followtumors. 8 We have used two endpoints for analyzing the ing treatment with dl70-3. Only weak anti-PyMT CTL effects of Ad-immunity on our tumor therapy: (1) tumor (Ͼ30% lysis at effector to target ratios of 90:1) was detectgrowth and (2) long-term survival. Tumors in both Adable in these animals ( Figure 3b ). The generation of antiimmune and nonimmune animals regressed following PyMT CTL in these experiments was similar to that treatment and responded equivalently to AdmIL-12.1 observed in nonimmune animals treated with either ( Figure 1 and Table 1 ). This response was specific to the AdmIL-12.1 or dl70-3 (C Addison, manuscript in AdmIL-12.1 virus because tumors treated with an E1-preparation). The presence of CTL specific for tumor antideleted control virus, dl70-3, grew progressively in both gen confirms the development of antitumor immunity in groups of mice. Long-term survival was also similar Ad5-immune animals following AdmIL-12.1 treatment. between the two groups (Figure 2 ), although the Adimmune mice treated with both dl70-3 and AdmIL-12.1
Dissemination of Ad following intratumoral administration appear to have slightly increased survival by comparison
To monitor virus dissemination following intratumoral to nonimmune controls. Thus, it appeared that preinjection in our model, we used a replication-defective immunity to Ad did not reduce the efficacy of the vector-expressing luciferase (AdDK2) as a marker to AdmIL-12.1 treatment indicating that humoral immunity detect infected cells in various tissues. Six animals to Ad may not present a serious barrier to the clinical received an intratumoral injection of AdDK2 (5 × 10 8 application of this treatment. p.f.u.), tissues were harvested from two animals at 24, 72 and 124 h after injection and assayed for luciferase content ( Figure 4 ). Twenty-four hours following virus inocuTumor regression in immune animals is associated with the development of antitumor immunity lation, very high levels of luciferase could be detected within the tumor (Ͼ1000 ng). Luciferase activity was also As further evidence that antitumor immunity was achieved in the Ad-immune animals treated with AdmILdetectable in other organs at 24 h indicating that the virus had disseminated, however, the extratumoral luciferase 12.1, animals which were cured by this treatment were Tumors initially regressed to less than 50% of the original volume but were not eliminated and eventually returned.
c Tumors displayed no change in size for at least 2 weeks following treatment.
represented less than 1% of the total luciferase in the animal. The highest expression of luciferase outside the tumor at this time was found in the liver (5-6 ng) and the fatpad adjacent to the tumor (approximately 2-3 ng). By 72 h, luciferase expression was lower in the tumor (800-900 ng) and expression in the fatpad was reduced as well (0.005 ng). In contrast, the quantity of luciferase in the liver had increased to Ͼ1000 ng, indicating that a substantial amount of virus had disseminated from the tumor and was expressing in peripheral organs. High levels of expression seen in the liver are consistent with previous studies showing that the liver is the major site of infection following administration of Ad intravenously 12 or by intraperitoneal injection. 13 Similarly expression of luciferase was increased in the lung, spleen and kidney but these were not major sites of dissemination since the combined activity in these organs was Ͻ1% of the activity in the liver. By day 6, luciferase expression was reduced in all organs. The kinetics of 
Discussion
Ad vectors can disseminate following intratumoral injection and infect peripheral organs, although they used a Preclinical studies have clearly demonstrated that the presence of neutralizing Abs may be a major limiting fachigher virus load (2 × 10 9 p.f.u.). tor in effective Ad-mediated gene delivery in vivo. [3] [4] [5] This has led to speculation regarding the effectiveness of Ad5-Antibodies to adenovirus prevent virus dissemination We have shown that Ad immunization before therapy based gene therapy, as the majority of the population has been exposed to this virus during their lifetime. Howdoes not prevent regression following intratumoral injection of AdmIL-12.1. It would be expected that the circulever, these studies have focused on repetitive administration of Ad to tissues like the liver and the lungs which ating Abs generated following immunization could protect sites like the liver from disseminated virus which are in direct contact with the systemic circulation and mucosal surfaces and consequently are readily protected probably gains access to the organs through the bloodstream. To test this hypothesis, we repeated the experiby anti-Ad Abs. Solid tumors, on the other hand, are often poorly vascularized and therefore may not be penment outlined in the previous paragraph using Adimmune mice. Tumor-bearing animals, both naive and etrated by Abs to as high a degree as other tissues, so it is reasonable to postulate that the effects of neutralizing Ad-immune, received an inoculum of 5 × 10 8 p.f.u. AdDK2 intratumorally. Twenty-four and 72 h later, Abs would be reduced within the microenvironment of the tumor. tissues were harvested, homogenized and assayed for luciferase activity. At 24 h, when we observed peak transTo examine the effects of Ad immunity on tumor gene therapy using an Ad expressing IL-12 (AdmIL-12.1), we gene expression in the tumor tissue, total luciferase within the tumors of immunized mice was only reduced immunized animals before inoculation with tumor cells. Once the tumors had established, the vector was adminisby an average of 2.4-fold compared to nonimmune animals (compare 1282 ± 273 ng luciferase in nonimmune tered directly into the tumor. The efficacy of the treatment did not appear to be diminished in the immune animals (n = 4) to 544 ± 195 in Ad-immune animals (n = 4); Figure 5a ). At 72 h, when the expression within animals, supporting our hypothesis that the neutralizing Abs may not be a major limitation in the context of the the liver was maximal, transgene expression in the liver was reduced by Ͼ1000-fold (compare 762 ± 265 ng in tumor nodule. The incidence of tumor regression in both Ad-immune and nonimmune groups was between 60 nonimmune animals (n = 7) to 0.29 ± 0.09 ng in Adimmune animals (n = 4); Figure 5b ) while tumor-associaand 70%, consistent with our previous observations. 8 The results obtained with the nonimmune group (no permated luciferase was only 6.8-fold lower in the Ad-immune mice (compare 762 ± 246 in nonimmune animals (n = 7) nent cures) differ from results reported in a previous publication in which a cure rate of approximately 30% to 113 ± 71 in Ad-immune animals (n = 4)). Thus, it appeared that the inhibitory effect of the neutralizing was obtained for nonimmune mice treated with AdmIL-12.1. The previous study involved a larger cohort (36 antibodies was much greater in the liver than in the tumor. Similarly, dissemination of AdDK2 to other mice) compared to the current study (16 mice) and we have found that although the overall cure rate with organs (spleen, lung, kidney) in the Ad-immune mice was also reduced (data not shown). Thus, Ad-immunity AdmIL-12.1 is approximately 30-40%, this parameter can fluctuate from one experiment to the next. In some appears to be beneficial in this setting by inhibiting the experiments we failed to achieve permanent cures while response alone, however, was not sufficient to cause tumor regression. in others 100% of the treated tumors underwent complete and permanent regression (J Bramson, unpublished Previously, Toloza et al, 14 using a viral load of 2 × 10 9 p.f.u. per tumor, have demonstrated that an Ad vector observations). Although it may seem that the results of the AdmIL-12.1 are variable, it should be noted that in can disseminate from the site of the tumor and infect peripheral organs. We found that even with a lower dose both the present and previous reports the incidence of tumor regression was between 60 and 80% of the AdmIL-(5 × 10 8 p.f.u. per tumor), the virus can still disseminate and infect peripheral organs such as the liver and the 12.1-treated animals and these animals survived at least twice as long as the dl70-3 controls. Thus, while there was spleen. Quite strikingly, the transgene expression in the liver at day 3 was almost equal to that in the tumor and variability in the frequency of complete cures without relapse, the outcome of the AdmIL-12.1 therapy in terms in certain animals it was greater. In the context of using Ad vectors for gene therapy of solid tumors, it had of tumor regression and increased survival is highly reproducible and is not impaired when animals are always been hoped that the virus would primarily infect the tissues in the vicinity of the site of inoculation. Howimmunized against Ad before therapy.
To make a better assessment of the effect of Adever, it is quite clear from both sets of studies that the virus can enter the circulation following intratumoral immunity on transgene expression in the tumor, we used a luciferase expression vector (AdDK2) to allow quantiadministration and infect peripheral organs. The observed dissemination is probably due to incomplete fication of transgene expression. By analyzing peak luciferase levels in the tumor, we found that expression adsorption at the site of injection since we have used an E1-deleted replication-defective Ad in a species which is was only reduced an average of 2.4-fold in tumors of Adimmune animals compared to naive mice. It is interesting nonpermissive for viral replication. One danger of circulating virus is that it will infect the liver giving rise to that the IL-12 therapy was not affected by the state of immunity of the animal even though expression was inflammation and damage. We have found that liver damage is apparent following in vivo delivery of Ad vecreduced in Ad-immune animals. There are at least two possible explanations for this: first, the dose of virus we tors regardless of the route of administration (footpad, intramuscular or subcutaneous). 15 This trauma to the are using is above the minimal amount required to induce an effective response. We have found that liver can then be compounded by the nature of the transgene, which in the case of cancer gene therapy may 2.5 × 10 8 p.f.u. AdmIL-12.1 is as effective as the dose we used in these studies, 5 × 10 8 p.f.u. 8 Second, adminisencode a cytokine or prodrug activating enzyme. Thus, disseminated virus may be a concern to the health of tration of Ad5 to the airway mucosae would result in the development of antiviral CTL, 3 and T cell responses the patient. As we discussed above, the presence of neutralizing against the Ad vector in the tumor could make up for the loss of IL-12 expression. Immune cells responding to Abs has been found to be inhibitory to successful Admediated gene transfer to the liver. When we examined Ad-infected cells could clear the infected cells and secrete cytokines such as IL-2 and IFN-␥ into the microenvirondissemination of AdDK2 by monitoring transgene expression in the liver, we found drastically reduced levment of the tumor which could act as an adjuvant to the IL-12 being expressed by the AdmIL-12.1 vector. Consistels in the livers of Ad-immune mice. While peak transgene expression was only reduced by 2.4-fold in the ent with this hypothesis, tumor-bearing Ad-immune mice treated with the control virus (dl70-3) survived tumors of immune animals, peak expression in the liver was reduced by Ͼ1000-fold. Therefore, the presence of longer than the respective nonimmune mice. The anti-Ad neutralizing Abs to Ad was found to be protective to the the E1 region of AdmIL12.1 and the IL-12 p40 subunit cassette is in the E3 region. Expression of each IL-12 host by inhibiting the dissemination of virus and spurious expression in peripheral organs. Our observations cDNA is driven by the human cytomegalovirus (HCMV) immediate-early gene promoter and terminated by the indicate that if organ toxicity is observed during the course of the clinical trials, it may be beneficial to immunpolyadenylation signal of SV40 and transcription is in the same direction as the E1 and E3 transcription units they ize patients undergoing Ad-based therapies before the initiation of the clinical protocol. Alternatively, techreplace. The luciferase expressing virus, AdDK2, contains an expression cassette in E1 consisting of the murine niques for passive immunity may be considered which would simply involve administration of anti-Ad polycytomegalovirus immediate-early promoter, the cDNA for firefly luciferase, and the polyadenylation signal of serum during the first few days or weeks of treatment.
The present studies have further substantiated the SV40. 24 AdLacZ is a replication-competent virus which contains an expression cassette encoding the E. coli ␤-approach of using Ad vectors for cancer gene therapy. It is clear that, at least for solid tumors, the presence of Adgalactosidase enzyme in E3. 25 The control adenovirus, dl70-3, is a mutant of Ad5 deleted in E1 and having a immunity may not be the impediment that was originally expected. Although peak expression was slightly reduced deletion/substitution in E3. 23 in the tumors of Ad-immune individuals, it should be possible to increase expression levels by boosting the Neutralizing antibody assay Serum samples were tested for neutralizing antibodies virus inoculum. The immune response against Ad antigens in virally infected cells could also limit therapies using an assay developed by L Prevec at McMaster University (unpublished). Serial five-fold dilutions of serum where long-term expression is important. Fortunately, the advent of nth generation viruses, which are fully were prepared in PBS with Mg ++ and Ca ++ (PBS ++ ). An aliquot of 150 l of diluted serum was mixed with a deleted of viral genes, should overcome that obstacle. [16] [17] [18] [19] In the absence of viral gene expression, Ad-immune indi-150 l aliquot of AdLacZ diluted to 7. 
Materials and methods
100 mm sodium phosphate buffer (pH 7.5) was added to each well and the plates were incubated at 37°C for 5 Animals, cell culture and reagents min. A 330 l aliquot of the substrate solution (4 mg/ml Six-to 8-week-old FVB/n female mice were obtained O-nitrophenol-␤-d-galactopyranoside (Sigma, Oakville, from Taconic Farms (Germantown, NY, USA) and Ontario, Canada) in 100 mm sodium phosphate buffer, housed in a specific pathogen-free facility until use. The pH 7.5), was then added to each well and incubated at 293 cells (adenoviral E1 transformed human embryonic 37°C for 1 h. The reaction was terminated by the addition kidney cells 20 ) were maintained in F-11 medium supof 430 l of 1 m Na 2 CO 3 and the optical density of the plemented with 10% newborn bovine serum. The target solution in each well was measured at 450 nm. The relalines for the CTL assay, PT0516 and 516MT3, are nontive absorbance for each dilution of anti-serum is tumor kidney fibroblast lines derived from an FVB presented as a fraction of the absorbance produced using mouse (C Addison, manuscript in preparation). The a corresponding dilution of control serum. The titer of 516MT3 cell line was generated by stably transfecting the neutralizing Ab was expressed as the inverse of the PT0516 cells with the polyoma middle T cDNA (PyMT). dilution required to produce 50% reduction in lacZ The PT0516, 516MT3 and Hela cells were cultured in ␣-expression as measured by absorbance at 450 nm. MEM supplemented with 10% fetal calf serum (FCS). Splenocyte culture was performed in RPMI-1640 with Tumor studies 10% FCS, 20 mm HEPES, 50 m ␤-mercaptoethanol. All
The tumor model used in this study is based on a transcell culture medium was supplemented with 2 mm l-glugenic mouse strain which harbors the PyMT gene under tamine, 100 g/ml penicillin and 100 U/ml streptomycin.
the control of the mouse mammary tumor virus long terCell culture media, reagents and Nunc tissue culture disminal repeat. 18 Female transgenic mice develop multifohes were obtained from Life Technologies (Gaithersburg, cal mammary carcinomas by 8-10 weeks of age at which MD, USA).
point the tumors are excised and transplanted ectopically to syngeneic FVB mice (eg by subcutaneous injection of single cell suspensions into the hind flanks), where they Adenoviral vectors Viruses were propagated on 293 cells and purified by ceswill induce tumors and grow indefinitely (typically the animals must be killed at 40-60 days). Briefly, tumors ium chloride gradient centrifugation as described. 21 Construction and characterization of an Ad vector were established in syngeneic mice as follows: tumors were excised from dead transgenic mice and a single cell (AdmIL12.1) expressing murine IL-12 has been described previously. 22 The Ad5-based recombinant system used to suspension was prepared as described. 6 An aliquot of 10 6 tumor cells was injected subcutaneously in the right hind produce these vectors allows for the insertion of expression cassettes in either the E1 or E3 region of Ad5. 23 flank of normal FVB mice. Randomly selected animals were immunized intranasally with 10 l of wild-type The expression cassette for the p35 subunit of IL-12 is in
